Investors 2016-12-09T07:33:03+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

ASX Announcement – CEO presentation at the Gold Coast Investment Showcase

Dimerix CEO, Kathy Harrison will present at the Gold Coast Investment Showcase this morning. The presentation is available here.

ASX Announcement – CEO Kathy Harrison on Proactive Investors Stocktube

Dimerix today published a recorded interview with Chief Executive Officer Kathy Harrison. The recent interview highlighted a number of important points including: − the innovative clinical and commercial development pathway for Dimerix’s lead compound (DMX-200) [...]

ASX Announcement – Publication of Receptor-HIT research

Dimerix Limited today announced the publication of important research by Chief Scientific Advisor, Associate Professor Kevin Pfleger and colleagues in the leading peer reviewed journal Scientific Reports. Read the full announcement here.

ASX Announcement – Dimerix hosts NephCure meeting

Dimerix hosts US key opinion leader meeting with NephCure Kidney International focused on development path of DMX-200 in kidney disease. Read the full press release here.

Read More

Media Coverage

Invitation to Gold Coast Investment Showcase

Read this invitation here.

Change of Venue for Sydney Shareholder Q&A

Read this announcement here. 

NDF Research Analyst Report March 2017

Read the report on their website. 

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates